Ge Long Hui A P P·2025-12-03 08:52Core Viewpoint - Fosun Pharma has received approval from the National Medical Products Administration for clinical trials of FXS887, an innovative oral small molecule drug aimed at treating advanced malignant solid tumors, with no similar drugs approved globally as of the announcement date [1] Company Summary - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is responsible for the development of FXS887 [1] - FXS887 is a self-developed drug by the company and its subsidiaries, indicating a strong focus on innovation in oncology [1] Industry Summary - The approval of FXS887 marks a significant milestone as there are currently no approved small molecule inhibitors targeting the same pathway for monotherapy or combination therapy in the global market [1]